137 related articles for article (PubMed ID: 29551361)
1. EMA guidance on radium-223 dichloride in prostate cancer.
Gourd E
Lancet Oncol; 2018 Apr; 19(4):e190. PubMed ID: 29551361
[No Abstract] [Full Text] [Related]
2. eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer.
Shore ND; Tutrone RF; Mariados NF; Nordquist LT; Mehlhaff BA; Steere KJ; Harrelson SS
Clin Genitourin Cancer; 2018 Apr; 16(2):149-154. PubMed ID: 29196208
[TBL] [Abstract][Full Text] [Related]
3. Interim Results From ERADICATE: An Open-Label Phase 2 Study of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Castration-Resistant Prostate Cancer Subjects With Symptomatic Bone Metastases.
Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):3-7. PubMed ID: 27167841
[No Abstract] [Full Text] [Related]
4. Highlights in Metastatic Prostate Cancer From the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: Commentary.
Shore ND
Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):17-9. PubMed ID: 27167847
[No Abstract] [Full Text] [Related]
5. Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit.
Dalla Volta A; Formenti AM; Berruti A
Eur Urol; 2019 Jun; 75(6):894-895. PubMed ID: 30711330
[TBL] [Abstract][Full Text] [Related]
6. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
Nilsson S
Expert Opin Drug Saf; 2015 Jul; 14(7):1127-36. PubMed ID: 26022669
[TBL] [Abstract][Full Text] [Related]
7. The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.
Wilson JM; Parker C
Expert Rev Anticancer Ther; 2016 Sep; 16(9):911-8. PubMed ID: 27501059
[TBL] [Abstract][Full Text] [Related]
8. Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.
Vogelzang NJ
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):809-819. PubMed ID: 28649893
[TBL] [Abstract][Full Text] [Related]
9. Dosing, administration, and safety of radium-223: How I do it.
Dan TD; Doyle L; Raval AJ; Pridjian A; Gomella LG; Den RB
Can J Urol; 2016 Jun; 23(3):8301-5. PubMed ID: 27347625
[TBL] [Abstract][Full Text] [Related]
10. Radium - 223 (Xofigo) for prostate cancer.
Med Lett Drugs Ther; 2013 Sep; 55(1426):79-80. PubMed ID: 24081388
[No Abstract] [Full Text] [Related]
11. Prostate cancer - Therapy with radium-223.
Brito AE; Amorim BJ; Martello M; Bernardo WM; Etchebehere E;
Rev Assoc Med Bras (1992); 2017 Dec; 63(12):1019-1023. PubMed ID: 29489974
[No Abstract] [Full Text] [Related]
12. Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
George DJ
Clin Adv Hematol Oncol; 2019 Jul; 17(7):382-385. PubMed ID: 31449503
[No Abstract] [Full Text] [Related]
13. Radium Ra 223 dichloride in castration-resistant prostate cancer.
Joung JY; Ha YS; Kim IY
Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
[TBL] [Abstract][Full Text] [Related]
15. Radium 223 dichloride for prostate cancer treatment.
Deshayes E; Roumiguie M; Thibault C; Beuzeboc P; Cachin F; Hennequin C; Huglo D; Rozet F; Kassab-Chahmi D; Rebillard X; Houédé N
Drug Des Devel Ther; 2017; 11():2643-2651. PubMed ID: 28919714
[TBL] [Abstract][Full Text] [Related]
16. Phase II Clinical Study of Radium-223 Chloride (BAY 88-8223) in Japanese Patients With Symptomatic Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases.
Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):15-6. PubMed ID: 27167846
[No Abstract] [Full Text] [Related]
17. Long-term abiraterone withdrawal syndrome.
Marin S; Querol R; Campins L; Miarons M; Font A; Lianes P
J Clin Pharm Ther; 2018 Oct; 43(5):714-716. PubMed ID: 29722038
[TBL] [Abstract][Full Text] [Related]
18. Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
Nilsson S
Am Soc Clin Oncol Educ Book; 2014; ():e132-9. PubMed ID: 24857093
[TBL] [Abstract][Full Text] [Related]
19. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS
Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059
[TBL] [Abstract][Full Text] [Related]
20. Management of bone metastases in prostate cancer: a review.
Bienz M; Saad F
Curr Opin Support Palliat Care; 2015 Sep; 9(3):261-7. PubMed ID: 26262831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
